cd-26

MGCD-265 analog (Glesatinib) 是一种口服生物可利用的多靶点酪氨酸激酶抑制剂，具有抗肿瘤活性，对 c-Met 和 VEGFR2 的 IC50 分别为 29 nM 和 10 nM。

CD2665 是一种具有口服活性的视黄酸受体 (RAR) 拮抗剂。对于 RARγ 和 RARβ，Kis 为 110 nM 和 306 nM。

Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.

Glesatinib is an orally active and potent dual inhibitor of MET SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.

Enavatuzumab (PDL192) 是一种人源化抗 TWEAK 受体单克隆抗体，具有抗肿瘤活性，通过主动募集和激活髓系效应子来杀死肿瘤细胞。Enavatuzumab 通过直接的 TweakR 信号和抗体依赖性细胞介导的细胞毒性 (ADCC) 诱导肿瘤生长抑制，抑制尤文肉瘤细胞系 RD-ES 的迁移能力，可用于研究晚期实体瘤。

Cyclic di-UMP is a pyrimidine-containing cyclic dinucleotide (CDN).1It is produced by bacterial cGAS DncV-like nucleotidyltransferases (CD-NTases), such as LpCdnE02 fromL. pneumophila, and binds to cGAS, in the apo or dsDNA-bound forms, with reduced affinity compared to 2'3'-cGAMP or 3'3'-cGAMP .1,2Cyclic di-UMP is intended for use as a negative control for cyclic di-GMP signaling. 1.Whiteley, A.T., Eaglesham, J.B., de Oliveira Mann, C.C., et al.Bacterial cGAS-like enzymes synthesize diverse nucleotide signalsNature564(7747)194-199(2019) 2.Hall, J., Ralph, E.C., Shanker, S., et al.The catalytic mechanism of cyclic GMP-AMP synthase (cGAS) and implications for innate immunity and inhibitionProtein Sci.26(12)2367-2380(2017)